Corporate News Report – Kyverna Therapeutics
Kyverna Therapeutics (ticker KYTX) experienced a decline of 3.31 % over the 24‑hour period ending at 04:00 PM Central Europe on Friday, 23 March 2026. The stock is currently priced at USD 5.49 on major exchanges.
- Shares outstanding: 61.8 million
- Market capitalization: USD 361.2 million
- Trading volume (last 24 hours): USD 4.8 million
- Price change since the end of last month: down 22.24 %
- 200‑day simple moving average: USD 8.19
- 52‑week high: USD 13.67 (15 December 2025)
- 52‑week low: USD 5.61 (14 October 2026)
Comparison with Peer Stocks (last 24 hours)
| Ticker | Price Change | Current Price | Market Capitalization | Additional Notes |
|---|---|---|---|---|
| EIKN | +3 % | USD 7.77 | USD 433.3 million | – |
| SGU | +0.46 % | USD 13.02 | USD 425.9 million | P/E ratio: 6.29 |
| BMRC | +2.63 % | USD 27.55 | USD 431.4 million | – |
| MBUU | +3.75 % | USD 22.18 | USD 429.8 million | P/E ratio: 304.09; FY 2027 Q1 results announced for 05 November 2026; conference call scheduled 08:30 AM ET |
| TECX | +0.05 % | USD 20.52 | USD 427 million | – |
Company Overview
Kyverna Therapeutics Inc. is a U.S.-based biotechnology firm. Its initial public offering was slated for February 8 2024 on the Nasdaq stock exchange. The company focuses on the development of therapies for oncology and immunology indications.
